Abstract
Background Long COVID (LC) patients frequently suffer from neuropsychiatric symptoms, including depression, anxiety, and chronic fatigue syndrome (CFS), relabeled as the physio-affective phenome of LC. Activated immune-inflammatory pathways and insulin resistance key play a role in these physio-affective symptoms due to LC.
Aims To examine the associations between the Hamilton Depression (HAMD), Hamilton Anxiety (HAMA) and Fibro-Fatigue (FF) Rating Scale scores and serum C-reactive protein (CRP), prostaglandin E2 (PGE2), galanin-galanin receptor 1 (GAL-GALR1) signaling, insulin resistance, insulin-like growth factor (IGF-1), plasminogen activator inhibitor-1 (PAI1), and damage biomarkers such as S100B and neuron-specific enolase (NSE) in 90 subjects 3-6 months after acute SARS-CoV-2 infection.
Results LC patients show higher HAMD, HAMA, and FF scores, CRP, PGE2, GAL-GALR1 signaling, insulin resistance, PAI1, NSE, and S100B than participants without LC. The HAMD/HAMA/FF scores were significantly correlated with PGE, CRP, GAL, GALR1, insulin resistance, and PAI1 levels, and a composite score based on peak body temperature (PBT) – oxygen saturation (SpO2) (PBT/SpO2 index) during the acute infectious phase. A large part of the variance in the affective and CFS symptoms (33.6%-42.0%) was explained by a combination of biomarkers; the top-3 most important biomarkers were GAL-GALR1 signaling, PGE2, and CRP. Inclusion of the PBT/SpO2 index increased the prediction considerably (55.3%-67.1%). The PBT/SpO2 index predicted the increases in GAL-GALR1 signaling.
Conclusions These findings suggest that the affective symptoms and CFS of Long COVID are largely the consequence of activated immune-inflammatory pathways, metabolic aberrations, and the severity of the inflammation during acute SARS-CoV-2 infection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There was no funding for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study received approval from the Kerbala Health Directorate-Training and Human Development Center (Document No.0030/2023) and the institutional ethics committee of the University of Kufa (1657/2023).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
https://scholar.google.co.th/citations?user=1wzMZ7UAAAAJ&hl=th&oi=ao Highly cited author: 2003-2023 (ISI, Clarivate) ScholarGPS: Worldwide #1 in molecular neuroscience; #1/4 in pathophysiology Expert worldwide medical expertise ranking, Expertscape (December 2022), worldwide: #1 in CFS, #1 in oxidative stress, #1 in encephalomyelitis, #1 in nitrosative stress, #1 in nitrosation, #1 in tryptophan, #1 in aromatic amino acids, #1 in stress (physiological), #1 in neuroimmune; #2 in bacterial translocation; #3 in inflammation, #4-5: in depression, fatigue and psychiatry.
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos